[go: up one dir, main page]

ES2171923T3 - Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. - Google Patents

Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.

Info

Publication number
ES2171923T3
ES2171923T3 ES97916380T ES97916380T ES2171923T3 ES 2171923 T3 ES2171923 T3 ES 2171923T3 ES 97916380 T ES97916380 T ES 97916380T ES 97916380 T ES97916380 T ES 97916380T ES 2171923 T3 ES2171923 T3 ES 2171923T3
Authority
ES
Spain
Prior art keywords
talidomide
medicines
profarms
preparation procedure
active principles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916380T
Other languages
English (en)
Inventor
Johannes Schneider
Werner Winter
Stephan Wnendt
Kai Zwingenberger
Kurt Eger
Michaela Akermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2171923T3 publication Critical patent/ES2171923T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE DESCRIBEN PRECURSORES DE TALIDOMIDA DE FORMULA (I), PROCEDIMIENTO PARA SU PREPARACION Y SU UTILIZACION COMO PRINCIPIO ACTIVO DE MEDICAMENTOS, EN LA CUAL R SIGNIFICA - CHR1 NHR2 O - (CH2)) N COOH, R1 ES H O ALQUILO DE C1-4 , R2 ES H, ALQUILO DE C1-3 , C(O) - CH2 NHR3 O UN GRUPO PROTECTOR DE AMINO, R3 ES H O UN GRUPO PROTECTOR DE AMINO Y N ES UN NUMERO ENTERO ENTRE 2 Y 4, EN FORMA DE SUS BASES O SALES DE ACIDOS FISIOLOGICOS.
ES97916380T 1996-04-09 1997-03-22 Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. Expired - Lifetime ES2171923T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Publications (1)

Publication Number Publication Date
ES2171923T3 true ES2171923T3 (es) 2002-09-16

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916380T Expired - Lifetime ES2171923T3 (es) 1996-04-09 1997-03-22 Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.

Country Status (12)

Country Link
US (1) US6417197B1 (es)
EP (1) EP0892794B1 (es)
JP (1) JP2000508298A (es)
CN (1) CN1102931C (es)
AT (1) ATE212989T1 (es)
AU (1) AU707144B2 (es)
DE (2) DE19613976C1 (es)
DK (1) DK0892794T3 (es)
ES (1) ES2171923T3 (es)
HU (1) HUP9902181A3 (es)
PT (1) PT892794E (es)
WO (1) WO1997037988A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
CZ389398A3 (cs) * 1996-05-29 1999-07-14 Prototek, Inc. Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
CZ299808B6 (cs) * 1997-11-18 2008-12-03 Celgene Corporation Substituované 2-(2,6-dioxo-3-fluoropiperidin-3-yl)izoindoliny a jejich použití za úcelem snížení hladin TNFalfa
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO2001041755A2 (en) * 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ES2338534T3 (es) * 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US7973057B2 (en) * 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
CA2542653A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2648216C (en) 2006-04-13 2016-06-07 Michael Gutschow Tetrahalogenated compounds useful as inhibitors of angiogenesis
PE20140963A1 (es) * 2008-10-29 2014-08-06 Celgene Corp Compuestos de isoindolina para el tratamiento de cancer
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
KR20180099712A (ko) * 2016-01-08 2018-09-05 셀진 코포레이션 항증식성 화합물, 및 이의 약제학적 조성물 및 용도
WO2019036839A1 (zh) * 2017-08-21 2019-02-28 诺瑞特国际药业股份有限公司 泊马度胺衍生物及其制备方法
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
ES2098505T3 (es) * 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
JP2000508298A (ja) 2000-07-04
HUP9902181A2 (hu) 2000-04-28
CN1102931C (zh) 2003-03-12
EP0892794B1 (de) 2002-02-06
DE19613976C1 (de) 1997-11-20
AU707144B2 (en) 1999-07-01
US6417197B1 (en) 2002-07-09
HK1017350A1 (en) 1999-11-19
WO1997037988A1 (de) 1997-10-16
PT892794E (pt) 2002-07-31
DE59706313D1 (de) 2002-03-21
DK0892794T3 (da) 2002-04-15
HUP9902181A3 (en) 2002-11-28
AU2505297A (en) 1997-10-29
ATE212989T1 (de) 2002-02-15
EP0892794A1 (de) 1999-01-27
CN1215397A (zh) 1999-04-28

Similar Documents

Publication Publication Date Title
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
DK1165570T3 (da) Nye phosphorholdige prodrugs
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
BR9507755A (pt) Composições géis em bastão compreendendo gelificantes oticamente enriquecidos
MX9203653A (es) Composiciones amfotericas y formas polimericas de los alfa-hidroxiacidos.
ES2084944T3 (es) Amidas terapeuticas.
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
GT200100174A (es) Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados.
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
PA8504401A1 (es) Compuestos farmaceuticamente activos
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
BR0012429A (pt) Fórmulações para il-11
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
ES2061546T3 (es) Compuestos quelantes de piridoxamina, quelatos de manganeso (ii) y su uso como agentes de contraste de nmri.
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
DE69615555D1 (de) 6-carboxamido-dihydropyran-derivate
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
FR2653303B1 (fr) Agents edulcorants de grande stabilite derivant des acides l-aspartique et l-glutamique n-hydrocarbones 1-oxo-2-ramifies.
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
ES2038216T3 (es) Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
ES2054089T3 (es) Formulaciones orales liquidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 892794

Country of ref document: ES